Genetic Disease Focused Fulcrum Therapeutics Files for $86 Million IPO

Fulcrum Therapeutics filed the paperwork for there IPO to raise up to $86 million on 6/21/19. The company has three small molecule candidates in development that aim to treat the root cause of a genetically defined rare disease. Fulcrum intends to trade on NASDAQ under the symbol “FULC.”